UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 2, 2011

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer x

Accelerated filer o

Non-accelerated filer o

Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES o NO x

At November 7, 2011, 7,686,966,786 shares of the issuer s voting common stock were outstanding.

FORM 10-Q

For the Quarter Ended

October 2, 2011

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and nine months ended October 2, 2011 and October 3, 2010

Condensed Consolidated Balance Sheets as of October 2, 2011 and December 31, 2010

Condensed Consolidated Statements of Cash Flows for the nine months ended October 2, 2011 and October 3, 2010

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

40

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

41

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

79

Item 4.

Controls and Procedures

79

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

79

Item 1A.

Risk Factors

79

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

80

Item 3.

Defaults Upon Senior Securities

80

Item 5.

Other Information

80

Item 6.

Exhibits

80

Signature

81

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

Oct. 2,

2011

Oct. 3,

2010

Oct. 2,

2011

Oct. 3,

2010

Revenues

17,193

15,995

50,679

49,703

Costs and expenses:

Cost of sales(a)

3,679

3,790

11,177

11,676

Selling, informational and administrative expenses(a)

4,621

4,599

14,097

13,776

Research and development expenses(a)

2,188

2,188

6,516

6,590

Amortization of intangible assets

1,397

1,156

4,168

3,972

Acquisition-related in-process research and development

charges

74

Restructuring charges and certain acquisition-related costs

1,101

499

2,474

2,090

Other deductions net

538

2,349

1,778

3,036

Income from continuing operations before provision for taxes on income

3,669

1,414

10,469

8,489

Provision for taxes on income

1,235

558

3,223

3,165

Income from continuing operations

2,434

856

7,246

5,324

Discontinued operations:

(Loss)/income from discontinued operations net of tax

(13

26

39

76

Gain/(loss) on sale of discontinued operations net of tax

1,328

(11

1,316

(9

Discontinued operations net of tax

1,315

15

1,355

67

Net income before allocation to noncontrolling interests

3,749

871

8,601

5,391

Less: net income attributable to noncontrolling interests

11

31

24

Net income attributable to Pfizer Inc.

3,738

866

8,570

5,367

Earnings per share basic:(b)

Income from continuing operations attributable to Pfizer Inc.

common shareholders

0.31

0.11

0.92

0.66

Discontinued operations net of tax

0.17

0.17

0.01

Net income attributable to Pfizer Inc. common shareholders

0.48

0.11

1.09

0.67

Earnings per share diluted:(b)

Income from continuing operations attributable to Pfizer Inc.

common shareholders

0.31

0.11

0.91

0.66

Discontinued operations net of tax

0.17

0.17

0.01

Net income attributable to Pfizer Inc. common shareholders

0.48

0.11

1.08

0.66

Weighted-average shares used to calculate earnings per common share:

Basic

7,770

8,027

7,877

8,045

Diluted

7,810

8,057

7,925

8,079

Cash dividends paid per common share

0.20

0.18

0.60

0.54

(a)

Exclusive of amortization of intangible assets, except as disclosed in Note 11B. Goodwill and Other Intangible Assets: Other Intangible Assets.

(b)

EPS amounts may not add due to rounding.

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(millions of dollars)

Oct. 2,

2011

Dec. 31,

2010

(Unaudited)

Assets

Cash and cash equivalents

3,706

1,735

Short-term investments

25,257

26,277

Accounts receivable, less allowance for doubtful accounts

15,749

14,426

Short-term loans

184

467

Inventories

8,426

8,275

Taxes and other current assets

9,288

8,394

Assets of discontinued operations and other assets held for sale

122

1,439

Total current assets

62,732

61,013

Long-term investments and loans

9,468

9,747

Property, plant and equipment, less accumulated depreciation

17,721

18,645

Goodwill

45,409

43,928

Identifiable intangible assets, less accumulated amortization

55,597

57,555

Taxes and other noncurrent assets

5,205

4,126

Total assets

196,132

195,014

Liabilities and Shareholders Equity

Short-term borrowings, including current portion of long-term debt

5,637

5,603

Accounts payable

3,765

3,994

Dividends payable

1,601

Income taxes payable

2,215

951

Accrued compensation and related items

1,999

2,080

Other current liabilities

14,240

14,256

Liabilities of discontinued operations

151

Total current liabilities

27,856

28,636

Long-term debt

35,399

38,410

Pension benefit obligations

5,734

6,194

Postretirement benefit obligations

3,059

3,035

Noncurrent deferred tax liabilities

20,415

18,628

Other taxes payable

6,900

6,245

Other noncurrent liabilities

6,239

5,601

Total liabilities

105,602

106,749

Commitments and Contingencies

Preferred stock

46

52

Common stock

445

444

Additional paid-in capital

71,235

70,760

Employee benefit trusts

(3

(7

Treasury stock

(28,586

(22,712

Retained earnings

48,121

42,716

Accumulated other comprehensive loss

(1,211

(3,440

Total Pfizer Inc. shareholders equity

90,047

87,813

Equity attributable to noncontrolling interests

483

452

Total shareholders equity

90,530

88,265

Total liabilities and shareholders equity

196,132

195,014

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine Months Ended

(millions of dollars)

Oct. 2,

2011

Oct. 3,

2010

Operating Activities:

Net income before allocation to noncontrolling interests

8,601

5,391

Adjustments to reconcile net income before allocation to noncontrolling interests to net

cash provided by operating activities:

Depreciation and amortization

6,656

6,493

Share-based compensation expense

347

351

Asset write-offs and impairment charges

773

2,956

Acquisition-related in-process research and development charges

74

(Gain)/loss on sale of discontinued operations

(1,683

Deferred taxes from continuing operations

693

1,277

Other deferred taxes

175

Other non-cash adjustments

26

(135

Benefit plan contributions in excess of expense

(283

(706

Other changes in assets and liabilities, net of acquisitions and divestitures

(326

(10,514

Net cash provided by operating activities

14,979

5,196

Investing Activities:

Purchases of property, plant and equipment

(1,062

(966

Purchases of short-term investments

(13,456

(5,018

Proceeds from redemptions and sales of short-term investments net

17,458

9,493

Purchases of long-term investments

(3,446

(2,674

Proceeds from redemptions and sales of long-term investments

2,001

3,822

Acquisitions, net of cash acquired

(3,188

Proceeds from sale of business

2,376

Other investing activities

618

496

Net cash provided by investing activities

1,301

5,153

Financing Activities:

Increase in short-term borrowings

9,613

4,686

Principal payments on short-term borrowings net

(10,069

(9,265

Principal payments on long-term debt

(3,486

(4

Purchases of common stock

(5,789

(1,000

Cash dividends paid

(4,710

(4,544

Other financing activities

84

32

Net cash used in financing activities

(14,357

(10,095

Effect of exchange-rate changes on cash and cash equivalents

48

(56

Net increase in cash and cash equivalents

1,971

198

Cash and cash equivalents at beginning of period

1,735

1,978

Cash and cash equivalents at end of period

3,706

2,176

Supplemental Cash Flow Information:

Cash paid during the period for:

Income taxes

1,539

11,519

Interest

1,872

2,039

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month and nine-month periods ended August 28, 2011, and August 29, 2010. We have made certain reclassification adjustments to conform prior-period amounts to the current presentation, primarily related to discontinued operations (see Note 4. Discontinued Operations) and segment reporting (see Note 15. Segment, Product and Geographic Area Information).

On January 31, 2011, we completed the tender offer for all of the outstanding shares of common stock of King Pharmaceuticals, Inc. (King) and acquired approximately 92.5% of the outstanding shares for approximately $3.3 billion in cash. On February 28, 2011, we acquired the remaining outstanding shares of King for approximately $300 million in cash (for additional information, see Note 3. Acquisition of King Pharmaceuticals, Inc.). Commencing from January 31, 2011, our financial statements include the assets, liabilities, operating results and cash flows of King. Therefore, in accordance with our domestic and international reporting periods, our condensed consolidated financial statements for the nine months ended October 2, 2011 reflect approximately eight months of King s U.S. operations and approximately seven months of King s international operations.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2010.

Note 2. Adoption of New Accounting Standards

The provisions of the following new accounting standards were adopted as of January 1, 2011 and did not have a significant impact on our condensed consolidated financial statements:

New guidelines that address the recognition and presentation of the annual fee paid by pharmaceutical companies beginning on January 1, 2011 to the U.S. Treasury as a result of U.S. Healthcare Legislation. As a result of adopting this new standard, we are recording the annual fee ratably throughout the year in the Selling, informational and administrative expenses line item in our condensed consolidated statement of income.

An amendment to the guidelines that address the accounting for multiple-deliverable arrangements to enable companies to account for certain products or services separately rather than as a combined unit.

Note 3. Acquisition of King Pharmaceuticals, Inc.

On January 31, 2011 (the acquisition date), we completed the tender offer for all of the outstanding shares of common stock of King at a purchase price of $14.25 per share in cash and acquired approximately 92.5% of the outstanding shares. On February 28, 2011, we acquired all of the remaining shares of King for $14.25 per share in cash. As a result, the total fair value of consideration transferred for King was approximately $3.6 billion in cash ($3.2 billion, net of cash acquired).

King s principal businesses consist of a prescription pharmaceutical business focused on delivering new formulations of pain treatments designed to discourage common methods of misuse and abuse; the Meridian auto-injector business for emergency drug delivery, which develops and manufactures the EpiPen; an established products portfolio; and an animal health business that offers a variety of feed-additive products for a wide range of species.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date:

(millions of dollars)

Amounts

Recognized as of

Acquisition Date

(Provisional)

Working capital, excluding inventories

174

Inventories

340

Property, plant and equipment

412

Identifiable intangible assets, excluding in-process research and development

1,822

In-process research and development

312

Net tax accounts

(389

All other long-term assets and liabilities, net

101

Total identifiable net assets

2,772

Goodwill

783

Net assets acquired/total consideration transferred

3,555

As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $200 million, virtually all of which was expected to be collected.

Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of King includes the following:

the expected synergies and other benefits that we believe will result from combining the operations of King with the operations of Pfizer;

any intangible assets that do not qualify for separate recognition, as well as future, yet unidentified projects and products; and

the value of the going-concern element of King s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately).

Goodwill is not amortized and is not deductible for tax purposes. While the allocation of goodwill among reporting units is not complete, we expect that substantially all of the goodwill will be related to our biopharmaceutical reporting units (see Note 11. Goodwill and Other Intangible Assets for additional information).

The assets and liabilities arising from contingencies recognized at acquisition date, some of which are subject to change, are not significant to Pfizer s condensed consolidated financial statements.

The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:

Amounts for intangibles and inventory, pending finalization of valuation efforts;

Amounts for income tax assets, receivables and liabilities pending the filing of King s pre-acquisition tax returns and the receipt of information from taxing authorities, which may change certain estimates and assumptions used; and

The allocation of goodwill among reporting units.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Revenues from King are included in Pfizer s condensed consolidated statements of income from the acquisition date, January 31, 2011, through Pfizer s third-quarter 2011 domestic and international quarter-ends and were $357 million for the third quarter of 2011 and $938 million in the first nine months of 2011. We are no longer able to provide the results of operations attributable to King as those operations have now been substantially integrated into the larger Pfizer operation.

The following table presents supplemental pro forma information as if the acquisition of King had occurred on January 1, 2010:

Pro Forma Consolidated Results

Three Months

Ended

Nine Months Ended

(millions of dollars, except per share data)

Oct. 3,

2010

Oct. 2,

2011

Oct. 3,

2010

Revenues

16,335

50,788

50,749

Net income attributable to Pfizer Inc. common shareholders

854

8,769

5,163

Diluted earnings per share attributable to Pfizer Inc. common shareholders

0.11

1.11

0.64

The unaudited pro forma consolidated results do not purport to project the future results of operations of the combined company nor do they reflect the expected realization of any cost savings associated with the acquisition. The unaudited pro forma consolidated results reflect the historical financial information of Pfizer and King, adjusted for the following pre-tax amounts:

Elimination of King s historical intangible asset amortization expense (approximately $18 million in the third quarter of 2010, $6 million in the first nine months of 2011 and $98 million in the first nine months of 2010).

Additional amortization expense (approximately $48 million in the third quarter of 2010, $15 million in the first nine months of 2011 and $136 million in the first nine months of 2010) related to the fair value of identifiable intangible assets acquired.

Additional depreciation expense (approximately $9 million in the third quarter of 2010, $3 million in the first nine months of 2011 and $26 million in the first nine months of 2010) related to the fair value adjustment to property, plant and equipment acquired.

Adjustment related to the fair value adjustments to acquisition-date inventory estimated to have been sold (addition of $33 million charge in the third quarter of 2010, elimination of $146 million charge in the first nine months of 2011 and addition of $146 million charge in the first nine months of 2010).

Adjustment for acquisition-related costs directly attributable to the acquisition (addition of $11 million of charges in the third quarter of 2010, elimination of $205 million of charges in the first nine months of 2011 and addition of $205 million of charges in the first nine months of 2010, reflecting charges incurred by both King and Pfizer).

Note 4. Discontinued Operations

We evaluate our businesses and product lines periodically for their strategic fit within our operations. In 2011, we decided to sell our Capsugel business. In connection with the decision to sell this business, for all periods presented, the operating results associated with this business have been reclassified into Discontinued operations net of tax in the Condensed Consolidated Statements of Income, and the assets and liabilities associated with this business have been reclassified into Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the Condensed Consolidated Balance Sheets.

On April 4, 2011, we announced that we had entered into an agreement to sell Capsugel to an affiliate of Kohlberg Kravis Roberts & Co. L.P. for approximately $2.4 billion in cash. The transaction closed on August 1, 2011.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following amounts, substantially all of which relate to our Capsugel business, have been segregated from continuing operations and included in Discontinued operations net of tax in our Condensed Consolidated Statements of Income:

Three Months Ended

Nine Months Ended

(millions of dollars)

Oct. 2,

2011

Oct. 3,

2010

Oct. 2,

2011

Oct. 3,

2010

Revenues

116

176

507

545

Pre-tax (loss)/income from discontinued operations

(7

29

78

106

Provision for taxes on income(a)

39

30

(Loss)/income from discontinued operations net of tax

(13

26

39

76

Pre-tax gain/(loss) on sale of discontinued operations

1,695

(12

1,683

(9

Provision/(benefit) for taxes on income(b)

367

(1

367

Discontinued operations net of tax

1,315

15

1,355

67

(a)

Includes a deferred tax expense of $13 million for the first nine months of 2011.

(b)

Includes a deferred tax expense of $162 million for the third quarter and first nine months of 2011.

The following assets and liabilities, which in 2010 include the assets and liabilities related to our Capsugel business, have been segregated and included in Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in our Condensed Consolidated Balance Sheets:

(millions of dollars)

Oct. 2,

2011

Dec. 31,

2010

Accounts receivable

186

Inventories

130

Taxes and other current assets

12

47

Property, plant and equipment

110

1,009

Goodwill

19

Identifiable intangible assets

Taxes and other noncurrent assets

45

Assets of discontinued operations and other assets held for sale

122

1,439

Current liabilities

124

Other liabilities

27

Liabilities of discontinued operations

151

The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities were not significant for the first nine months of 2011 or 2010.

Note 5. Costs Associated with Cost-Reduction and Productivity Initiatives and Acquisition Activity

We incur significant costs in connection with acquiring businesses and restructuring and integrating acquired businesses and in connection with our global cost-reduction and productivity initiatives. For example:

for our cost-reduction and productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems; and

for our acquisition activity, we typically incur costs that can include transaction costs, integration costs (such as expenditures for consulting and the integration of systems and processes) and restructuring charges, related to employees, assets and activities that will not continue in the combined company.

On February 1, 2011, we announced a new research and productivity initiative to accelerate our strategies to improve innovation and overall productivity in R&D by prioritizing areas with the greatest scientific and commercial promise, utilizing appropriate risk/return profiles and focusing on areas with the highest potential to deliver value in the near term and over time.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

We incurred the following costs in connection with our cost-reduction and productivity initiatives and acquisition activity, such as King (acquired in 2011) and Wyeth (acquired in 2009):

Three Months Ended

Nine Months Ended

(millions of dollars)

Oct. 2,

2011

Oct. 3,

2010

Oct. 2,

2011

Oct. 3,

2010

Transaction costs(a)

28

13

Integration costs(b)

187

231

567

650

Restructuring charges(c):

Employee termination costs

770

27

1,626

603

Asset impairments

99

174

157

677

Other

40

67

96

147

Restructuring charges and certain acquisition-related costs

1,101

499

2,474

2,090

Additional depreciation asset restructuring(d):

Cost of sales

68

241

411

367

Selling, informational and administrative expenses

39

27

69

190

Research and development expenses

146

25

378

45

Total additional depreciation asset restructuring

253

293

858

602

Implementation costs(e):

Selling, informational and administrative expenses

11

11

Research and development expenses

28

Total implementation costs

19

39

Total costs associated with cost-reduction and productivity initiatives and

acquisition activity

1,373

792

3,371

2,692

(a)

Transaction costs represent external costs directly related to acquired businesses and primarily include expenditures for banking, legal, accounting and other similar services.

(b)

Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes.

(c)

From the beginning of our cost-reduction and transformation initiatives in 2005 through October 2, 2011, Employee termination costs represent the expected reduction of the workforce by approximately 57,800 employees, mainly in manufacturing and sales and research, of which approximately 41,000 employees have been terminated as of October 2, 2011. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities.

The restructuring charges in 2011 are associated with the following:

For the three months ended October 2, 2011, Primary Care operating segment ($473 million), Specialty Care and Oncology operating segment ($186 million), Established Products and Emerging Markets operating segment ($65 million), Animal Health and Consumer Healthcare operating segment ($30 million), Nutrition operating segment ($2 million), research and development operations ($47 million income), manufacturing operations ($47 million) and Corporate ($153 million).

For the nine months ended October 2, 2011, Primary Care operating segment ($606 million), Specialty Care and Oncology operating segment ($228 million), Established Products and Emerging Markets operating segment ($80 million), Animal Health and Consumer Healthcare operating segment ($44 million), Nutrition operating segment ($4 million), research and development operations ($426 million), manufacturing operations ($203 million) and Corporate ($288 million).

The restructuring charges in 2010 are associated with the following:

For the three months ended October 3, 2010, Primary Care operating segment ($14 million), Specialty Care and Oncology operating segment ($53 million), Established Products and Emerging Markets operating segment ($14 million), Nutrition operating segment ($1 million), research and development operations ($17 million), manufacturing operations ($161 million) and Corporate ($8 million).

For the nine months ended October 3, 2010, Primary Care operating segment ($1 million), Specialty Care and Oncology operating segment ($99 million), Established Products and Emerging Markets operating segment ($23 million), Animal Health and Consumer Healthcare operating segment ($33 million), Nutrition operating segment ($12 million income), research and development operations ($239 million), manufacturing operations ($970 million) and Corporate ($74 million).

(d)

Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(e)

Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction and productivity initiatives.

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The components of restructuring charges associated with all of our cost-reduction and productivity initiatives and acquisition activity follow:

Costs Incurred

Activity

Accrual

(millions of dollars)

2005-2011

Through

Oct. 2,

2011(a)

As of

Oct. 2,

2011(b)

Employee termination costs

10,437

7,720

2,717

Asset impairments

2,465

2,465

Other

996

889

107

Total restructuring charges

13,898

11,074

2,824

(a)

Includes adjustments for foreign currency translation.

(b)

Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($1.1 billion).

Note 6. Other (Income)/Deductions Net

The following table sets forth details related to amounts recorded in Other deductions net:

Three Months Ended

Nine Months Ended

(millions of dollars)

Oct. 2,

2011

Oct. 3,

2010

Oct. 2,

2011

Oct. 3,

2010